Life Sciences

  • August 27, 2026

    Mead Johnson Nutrition Head Defends Formula In MDL Trial

    Mead Johnson's head of nutrition testified Thursday in a trial over whether its preterm infant formula led to a newborn's serious and ultimately fatal gut illness, saying she had no reasons to worry about the product's safety but acknowledging it carries a higher risk for the disease than human breast milk.

  • August 27, 2026

    5th Circ. Backs FDA, Pharma Cos. In GLP-1 Shortage Fight

    The U.S. Food and Drug Administration did not unlawfully remove blockbuster GLP-1 medications made by Eli Lilly & Co. and Novo Nordisk from the national drug shortage list, the Fifth Circuit ruled Thursday, handing a loss to compounding pharmacies that produce copycat doses of the drugs.

  • August 27, 2026

    Guardant Suits Against Tempus AI Clear Dismissal Bids

    A Delaware federal judge has refused to throw out litigation accusing Tempus AI Inc. of infringing Guardant Health Inc. patents covering technology used to analyze cancer-related genetic data and help guide testing and treatment.

  • August 27, 2026

    23andMe Judge Slows Estimation Of Calif. Data Breach Claim

    A Missouri bankruptcy judge ruled Thursday he would split a process for dealing with data breach claims brought by the state of California against 23andMe into two stages, saying he would first decide whether the bankruptcy trust for the DNA testing company should be allowed to estimate the state's claims for damages.

  • August 27, 2026

    Mich. Hospitals Defend CVS 340B Drug Savings Suit

    University of Michigan Hospitals and Health Centers urged a Michigan federal judge Wednesday to preserve its suit claiming that CVS Health Corp. diverted millions of dollars earmarked for indigent healthcare to itself, saying the conduct clearly amounts to a racketeering scheme.

  • August 27, 2026

    USPTO Sets Radiation Monitoring Patent Order As Informative

    The U.S. Patent and Trademark Office has added weight to a Patent Trial and Appeal Board order from earlier this year that undid a decision rejecting an RNA patent application.

  • August 27, 2026

    Rising Star: Goodwin's Heath Ingram

    Heath Ingram of Goodwin Procter LLP advised Avadel Pharmaceuticals on its launch of a U.S. Food and Drug Administration-approved narcolepsy drug and then its $2.37 billion sale to fellow Irish drugmaker Alkermes, earning him a spot among life sciences attorneys under age 40 honored by Law360 as Rising Stars.

  • August 26, 2026

    5th Circ. Upholds Drug Negotiations In Blow To Big Pharma

    Medicare's landmark program of drug price negotiations doesn't flout constitutional provisions involving the separation of powers, due process or excessive fines, the Fifth Circuit ruled late Wednesday, delivering a fresh blow to the pharmaceutical industry's campaign to tee up U.S. Supreme Court review.

  • August 26, 2026

    Eton's Galzin TM And False Ad Suit Survives Dismissal Bid

    Eton Pharmaceuticals can proceed with trademark infringement and false advertising claims accusing Extreme V of marketing a dietary supplement as a Wilson disease treatment, with a Michigan federal judge finding that Extreme V's defenses and factual challenges could not dispose of the case at the pleading stage.

  • August 26, 2026

    Humana Keeps Conspiracy Claims Against Mylan, Lannett

    A federal judge refused to grant Mylan and Lannett summary judgment on claims in Humana's suit alleging a conspiracy to fix the prices of generic drugs ahead of its bellwether trial, calling it premature and noting that the other parties did not join the motion.

  • August 26, 2026

    2nd Circ. Says Shield Law Covers Doctor In COVID Death Suit

    The Second Circuit on Wednesday affirmed the dismissal of a Connecticut estate's malpractice suit alleging a doctor negligently prescribed high doses of prednisone to an elderly COVID-19 patient who subsequently died of organ failure, finding the suit is barred under the Public Readiness and Emergency Preparedness Act.

  • August 26, 2026

    Idaho Abortion Ban Relief Narrowed To 1 Doctor

    An Idaho federal judge walked back his recent order barring the state from enforcing its near-total abortion ban in certain health-related circumstances, finding that precedent in the U.S. Supreme Court supported a narrower injunction.

  • August 26, 2026

    Rising Star: Sullivan & Cromwell's RuiHui 'Rachel' Yu

    RuiHui "Rachel" Yu of Sullivan & Cromwell LLP helped Chinese biotechnology company MediLink Therapeutics craft an agreement granting Roche exclusive rights to commercialize its lead antibody-drug conjugate outside China, earning her a spot among life sciences attorneys under age 40 honored by Law360 as Rising Stars.

  • August 26, 2026

    Pot Distributor Again Files Counterclaims In Contract Dispute

    A cannabis distributor has filed renewed counterclaims against its former consulting partner and a rival distributor, alleging that the rival deliberately interfered with an exclusivity agreement with the consulting partner.

  • August 25, 2026

    Albertsons Witness Says Co.'s Opioid Policies Beat Standards

    Albertsons' pharmacy policies for reviewing potentially suspicious opioid prescriptions "met or exceeded" the standard of care, an expert witness for the company testified Tuesday, on the 26th day of a bench trial in Washington's case accusing the pharmacy chain of fueling the state's opioid epidemic.

  • August 25, 2026

    Ex-Taro Exec Slips Some Generics Price-Fixing Claims

    A Connecticut federal judge gave a former Taro Pharmaceuticals USA Inc. marketing executive a partial victory in generic drug price-fixing litigation, tossing several claims by state attorneys general but allowing others to proceed after finding that a jury could conclude he joined certain conspiracies.

  • August 25, 2026

    Health Exec Says CFO, Atty Knew Wage Claim Was Wrong

    A former corporate officer has sued his ex-colleague and the colleague's attorney in Connecticut state court, alleging they named him as a personal defendant in a federal wage lawsuit without any factual basis and with the intent to pressure his company into settling claims it disputed.

  • August 25, 2026

    AIDS Org 'Had Its Chance' To Sue Express Scripts, Judge Says

    Express Scripts convinced a Missouri federal judge Tuesday to dismiss an AIDS Healthcare Foundation antitrust suit the judge said was precluded by a rejected earlier case in the same district raising the "same facts and circumstances" accusing the pharmacy benefit manager of imposing lower reimbursement rates on specialty pharmacies.

  • August 25, 2026

    Marijuana Rescheduling Critics Assail Government's Standard

    An attorney with the U.S. Drug Enforcement Administration told an administrative law judge that opponents to cannabis rescheduling could not use agency hearings to challenge federal health regulators' adoption of a new standard for assessing marijuana's medical use.

  • August 25, 2026

    23andMe, Calif. Spar Over Data Claims In Bankruptcy Court

    The bankruptcy trust for DNA testing company 23andMe and the state of California locked horns Tuesday over the debtor's plan to trim the size of claims that the state has asserted over a data breach in 2023.

  • August 25, 2026

    Lupin Beats Vertex's Patent Suit Over Cystic Fibrosis Drug

    A Delaware federal court has rejected Vertex Pharmaceuticals Inc.'s suit accusing Lupin Ltd. of infringing patents covering a cystic fibrosis treatment, with a judge saying Monday that Lupin's planned generic doesn't have the specific concentration of the drug covered by the patents.

  • August 25, 2026

    Abbott Cuts $88.5M Deal To End Investors' Formula Recall Suit

    Abbott Laboratories and a proposed class of shareholders have reached an $88.5 million settlement to resolve claims that the company misled investors about its safety practices ahead of the 2022 recall at its Sturgis, Michigan, infant formula plant, in a deal that comes a month after an Illinois federal judge tossed the suit.

  • August 25, 2026

    FDA Must Revisit Xifaxan Generic Exclusivity, DC Circ. Says

    The D.C. Circuit on Tuesday ordered the U.S. Food and Drug Administration to take another look at Norwich Pharmaceuticals' bid to bring a generic version of a prescription drug for irritable bowel syndrome to market, faulting the FDA's use of what the court said was an incorrect causation standard.

  • August 25, 2026

    Drugstores Beat Sun Pharma's $10M Racketeering Suit

    A New Jersey federal judge threw out Sun Pharmaceutical Industries Inc.'s suit against a group of pharmacies alleging they engaged in a criminal, years-long racketeering scheme that resulted in it paying more than $10 million in refunds for short-dated pharmaceutical products, ruling that the pharmacies were improperly joined together.

  • August 25, 2026

    McKesson Snags Precision Medicine Group In $2.25B Deal

    Healthcare services provider McKesson Corp., advised by Davis Polk & Wardwell LLP, on Tuesday unveiled plans to acquire clinical research and biopharmaceutical commercialization services business Precision Medicine Group for roughly $2.25 billion.

Expert Analysis

  • Series

    Law School's Missed Lessons: The Human Element

    Author Photo

    Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.

  • Avoid The Unexpected When Drafting License Agreements

    Author Photo

    The Delaware Court of Chancery's recent decision in Commave v. Zevrain raises several practice points for attorneys drafting commercial contracts, underscoring the importance of considering anti-assignment provisions, specific exclusions and potential carveouts when drafting license agreements or other commercial contracts, say attorneys at Hogan Lovells.

  • CMS Healthcare Enforcement Initiatives May Cause Disruption

    Author Photo

    The Centers for Medicare & Medicaid Services' recently announced enforcement actions against healthcare fraud mark a significant escalation, and CMS' prior approach in the hospice sector suggests that even compliant providers and suppliers should brace for impact, say attorneys at Morgan Lewis.

  • The Benefits Of Choosing A Niche Practice In The AI Age

    Author Photo

    As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.

  • How PBMs Can Adapt To Plan Sponsors' Disclosure Demands

    Author Photo

    As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.

  • What New Animal Welfare Enforcement Push Means For Cos.

    Author Photo

    The Trump administration's recently announced multiagency focus on violations of the Animal Welfare Act and related laws will likely lead to broader enforcement actions across industries, heightened scrutiny of compliance standards and a need for businesses to adopt effective risk management practices, says Shennie Patel at Crowell & Moring.

  • How To Engage With Gov't's Direct-To-Consumer Drug Policy

    Author Photo

    The U.S. Department of Health and Human Services' recent request for industry input on manufacturers' direct-to-consumer drug sales reflects the government's caution in this arena, and allows stakeholders a rare opportunity to help shape policy, says Mary Kohler at Kohler Health Law.

  • Series

    Podcasting Makes Me A Better Lawyer

    Author Photo

    Podcasting has changed how I ask questions and connect with people, sharpening my ability to listen without interrupting or prejudging, and bringing me closer to what law is meant to be: a human profession grounded in understanding, judgment and trust, says Donna DiMaggio Berger at Becker.

  • Patent Eligibility Bulletin: Steps To Consider As USPTO Shifts

    Author Photo

    Recent memoranda from the U.S. Patent and Trademark Office, along with some of the first patents issued under Director John Squires, indicate a recalibration of the subject matter eligibility landscape, signaling a renewed emphasis on concrete technological improvements and a potentially pro-AI stance, say attorneys at Banner Witcoff.

  • Tax Court Ruling Signals Cross-Border Loan Scrutiny

    Author Photo

    The U.S. Tax Court’s recent decision in Aventis v. Commissioner compounds ongoing regulatory focus on debt originations and should prompt practitioners to assess their existing cross-border lending structures for potential exposure to U.S. federal income tax, say attorneys at Eversheds.

  • Lessons From Justices' Split On Major Questions Doctrine

    Author Photo

    The justices' varied opinions in Learning Resources v. Trump, which held the International Emergency Economy Powers Act did not confer the power to impose tariffs, offer a meaningful window into the U.S. Supreme Court's perspective on the major questions doctrine that will likely shape lower courts' approach to executive action challenges, say attorneys at Venable.

  • Drug Wholesaler's DPA Shows Imperfect Efforts Still Count

    Author Photo

    Atlantic Biologicals’ recent deferred prosecution agreement with federal prosecutors for allegedly distributing controlled substances to pill mill pharmacies demonstrates that even subpar cooperation, when combined with genuine remediation and strategic advocacy, can yield outcomes that protect a company's long-term interests, says Jonathan Porter at Husch Blackwell.

  • Key Takeaways As HRSA Aims To Revive 340B Rebate Pilot

    Author Photo

    The U.S. Department of Health and Human Services' recent request for feedback on the 340B Rebate Model Pilot Program demonstrates that it intends to correct the model's procedural defects, which is positive news for participating manufacturers, but a setback for covered entities, say attorneys at Manatt.

  • When MDLs Drag, State Courts Can Speed Mass Tort Results

    Author Photo

    Understanding the structural dynamics that can delay resolution in multidistrict litigation is essential to understanding why a state court strategy is sometimes not merely attractive, but necessary for plaintiffs seeking timely and just outcomes, say attorneys at DiCello Levitt.

  • Leveraging MDLs And State Courts In Mass Tort Strategy

    Author Photo

    Multidistrict litigation's quiet drift from a pretrial coordination device to a de facto national court for mass torts poses a strategic question for plaintiffs counsel — whether an MDL will yield timely trials, meaningful accountability and fair value for clients, or whether a state court strategy will be more effective, say attorneys at DiCello Levitt.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.